Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

Pancreatic Adenocarcinoma Clinical Trial

— I-FLOAT  

Official title:

A Phase 1 Dose Finding Study of the gFOLFOXIRITAX Regimen Using UGT1A1 Genotype-directed Irinotecan With Fluorouracil, Leucovorin, Oxaliplatin and Taxotere in Patients With Untreated Advanced Upper Gastrointestinal Adenocarcinomas: The I-FLOAT Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04361708
• Other study ID #: IRB19-1292
• Status: Recruiting
• Phase: Phase 1
• Start date: May 8, 2020
• Est. completion date: May 2027

Study information

• Verified date: August 2023
• Source: University of Chicago
• Contact: Daniel Catenacci, MD
• Phone: 773-702-7596
• Email: dcatenacci[@]medicine.bsd.uchicago.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the proposed study is to establish the safety of combining irinotecan chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as the I-FLOAT study of gFOLFOXIRITAX) chemotherapies (leucovorin/folinic acid is a vitamin to make 5-FU work well).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: May 2027
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, gastroesophageal adenocarcinoma, cholangiocarcinoma, gallbladder adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with upper GI primary suspected), or other primary GI malignancy for which the treating physician feels that I-FLOAT is a reasonable therapeutic option.

2. Patients with a history of obstructive jaundice due to the primary tumor must have resolved to <1.5 X upper limit of normal and a metal biliary stent in place

3. Age greater than or equal to 18 years.

4. Eastern Cooperative Oncology Group (ECOG) performance status =1

5. Life expectancy > 3 months

6. Adequate organ function, as defined by each of the following:

Absolute neutrophil count (ANC) = 1500/uL Hemoglobin > 9g/dL (transfusion permitted with stability for > 1 week) Platelets > 100,000/uL Total bilirubin = 1.5 mg/dL AST and ALT = 2.5 X upper limit of normal; alkaline phosphatase = 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis. AST and ALT = 5 X upper limit of normal if hepatic metastases are present. Creatinine = 1.5 mg/dL

7. Measurable or non-measurable disease will be allowed.

8. Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment.

9. Negative serum or urine B-hCG pregnancy test at screening for patients of childbearing potential

10. Patients taking substrates, inhibitors, or inducers of CYP3A4 should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan.

Exclusion Criteria:

1. Prior radiation therapy for any cancer.

2. Prior chemotherapy for metastatic disease Recurrence of disease within 6 months of perioperative chemotherapy are eligible if other eligibility criteria are met

3. Inflammatory bowel disease (Crohn's disease, ulcerative colitis)

4. Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v. 4.0*). Pancreatic cancer patients with clinical evidence of pancreatic insufficiency must be taking pancreatic enzyme replacement.

5. Neuropathy, grade 2 or greater by NCI-CTCAE, v. 4.0.

6. Documented brain metastases

7. Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment.

8. Active uncontrolled bleeding.

9. Pregnancy or breastfeeding.

10. Major surgery within 4 weeks.

11. Previous or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the patient has been previously treated and the lifetime recurrence risk is less than 30%, and meets all other eligibility criteria.

Related Conditions & MeSH terms

• Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma
• Pancreatic Adenocarcinoma

Intervention

Drug:
• Oxaliplatin
Oxaliplatin will be administered on day 1 of each cycle at 85mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
• Docetaxel
Docetaxel will be administered on day 1 of each cycle at 25mg at dose level 1; 37.5 at dose level 2. The drugs will be given through the patient's Mediport.It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
• Leucovorin
Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
• Irinotecan
Irinotecan will be administered on day 1 of each cycle at 120mg/m2 for low risk group, 105mg/m2 for intermediate risk group, 45mg/m2 for high risk group . The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
• 5-Fluorouracil
5-FU is given as a continuous intravenous infusion over 2 days. Patient can receive the 2-day infusion as an outpatient. On day 3 of each cycle, the patient will return to the infusion center to have the infusion hook-up disconnected.

Locations

Country	Name	City	State
United States	The University of Chicago	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The maximum dose tolerated	To determine the maximum tolerated dose in the first month of therapy in each of the three main genotype groups (low, intermediate, and high risk) using genotype-guided dosing of irinotecan as part of the I-FLOAT regimen	1 month
Secondary	Cumulative dose of each chemotherapy drug	To determine the cumulative dose of each chemotherapy drug (irinotecan, 5-FU, oxaliplatin, docetaxel) administered in each genotype group over a period of 4 months (8 doses).	4 months
Secondary	Total duration of therapy	To determine the total duration of therapy, which would be administered perioperatively in future studies for the curative-intent setting.	18 months
Secondary	Overall Response Rate	To determine early efficacy (overall responsive rate, progression free survival, and overall survival) in all patients enrolled and treated in the study.	5 years
Secondary	Progression free survival rate	To determine early efficacy (overall responsive rate, progression free survival, and overall survival) in all patients enrolled and treated in the study.	5 years
Secondary	Overall survival rate	To determine early efficacy (overall responsive rate, progression free survival, and overall survival) in all patients enrolled and treated in the study.	5 years